151 related articles for article (PubMed ID: 22920399)
1. NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.
Roederer MW
Pharmacogenomics; 2012 Aug; 13(11):1307-13. PubMed ID: 22920399
[TBL] [Abstract][Full Text] [Related]
2. Integrating pharmacogenomics into electronic health records with clinical decision support.
Hicks JK; Dunnenberger HM; Gumpper KF; Haidar CE; Hoffman JM
Am J Health Syst Pharm; 2016 Dec; 73(23):1967-1976. PubMed ID: 27864204
[TBL] [Abstract][Full Text] [Related]
3. [Translational approach for pharmacogenomics and personalized medicine].
Zhang W; Zhou HH
Yao Xue Xue Bao; 2011 Jan; 46(1):1-5. PubMed ID: 21465801
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic testing and the prospect of individualized treatment.
Jonas DE; Wines R
N C Med J; 2013; 74(6):485-93. PubMed ID: 24316770
[TBL] [Abstract][Full Text] [Related]
5. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.
Squassina A; Manchia M; Manolopoulos VG; Artac M; Lappa-Manakou C; Karkabouna S; Mitropoulos K; Del Zompo M; Patrinos GP
Pharmacogenomics; 2010 Aug; 11(8):1149-67. PubMed ID: 20712531
[TBL] [Abstract][Full Text] [Related]
6. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.
Piana C; Surh L; Furst-Recktenwald S; Iolascon A; Jacqz-Aigrain EM; Jonker I; Russo R; van Schaik RH; Wessels J; Della Pasqua OE
J Clin Pharmacol; 2012 May; 52(5):704-16. PubMed ID: 21566202
[TBL] [Abstract][Full Text] [Related]
7. 4th Annual Pharmacogenomics and Medicine Lectures.
Oestreicher P
Pharmacogenomics; 2001 Aug; 2(3):291-6. PubMed ID: 11939134
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine policy challenges: measuring clinical utility at point of care.
van Rooij T; Wilson DM; Marsh S
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
[TBL] [Abstract][Full Text] [Related]
9. Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services.
Hicks JK; Stowe D; Willner MA; Wai M; Daly T; Gordon SM; Lashner BA; Parikh S; White R; Teng K; Moss T; Erwin A; Chalmers J; Eng C; Knoer S
Pharmacotherapy; 2016 Aug; 36(8):940-8. PubMed ID: 27312955
[TBL] [Abstract][Full Text] [Related]
10. Economic opportunities and challenges for pharmacogenomics.
Deverka PA; Vernon J; McLeod HL
Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
[TBL] [Abstract][Full Text] [Related]
11. A hub for bench-to-bedside pharmacogenomic-based research.
Voora D; Ginsburg GS
Pharmacogenomics; 2011 Aug; 12(8):1095-8. PubMed ID: 21843063
[TBL] [Abstract][Full Text] [Related]
12. Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine research.
Kennedy MA; Joyce PR; Begg EJ
Pharmacogenomics; 2012 Jun; 13(8):865-8. PubMed ID: 22676191
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations.
Manchikanti L
Pain Physician; 2008; 11(2):161-86. PubMed ID: 18354710
[TBL] [Abstract][Full Text] [Related]
14. Stakeholder views on pharmacogenomic testing.
Patel HN; Ursan ID; Zueger PM; Cavallari LH; Pickard AS
Pharmacotherapy; 2014 Feb; 34(2):151-65. PubMed ID: 24167008
[TBL] [Abstract][Full Text] [Related]
15. Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
Bottorff MB; Bright DR; Kisor DF
Pharmacotherapy; 2017 Sep; 37(9):1005-1013. PubMed ID: 28654154
[TBL] [Abstract][Full Text] [Related]
16. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacogenomics: hype or hope?].
Schwab M; Schaeffeler E; Zanger UM; Brauch H; Kroemer HK
Dtsch Med Wochenschr; 2011 Mar; 136(10):461-7. PubMed ID: 21365522
[TBL] [Abstract][Full Text] [Related]
18. Paediatric pharmacogenomics: an overview.
Hawcutt DB; Thompson B; Smyth RL; Pirmohamed M
Arch Dis Child; 2013 Mar; 98(3):232-7. PubMed ID: 23196740
[TBL] [Abstract][Full Text] [Related]
19. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
20. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
